Differential effects of teriparatide and alendronate on bone parameters in postmenopausal women with osteoporosis

被引：0
|
作者：
McClung, MR
Martin, JS
Meunier, PJ
Miller, PD
Haddock, L
Bandeira, F
Szejnfled, V
Donley, DW
Eriksen, EF
机构：
[1] Oregon Osteoporosis Ctr, Portland, OR USA
[2] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[3] Fac Med R Laennec, INSERM, U403, Lyon, France
[4] Fac Med R Laennec, Lab Histodynam Osseuse, Lyon, France
[5] Colorado Ctr Bone Res, Lakewood, CO USA
[6] Hosp Agamenon Magalhaes, Recife, PE, Brazil
[7] Escola Paulista Med, BR-04023 Sao Paulo, Brazil
来源：
OSTEOPOROSIS INTERNATIONAL | 2003年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S5 / S5
页数：1
相关论文
共 50 条
  • [41] Effects of Teriparatide Treatment and Discontinuation in Postmenopausal Women and Eugonadal Men with Osteoporosis
    Leder, Benjamin Z.
    Neer, Robert M.
    Wyland, Jason J.
    Lee, Hang W.
    Burnett-Bowie, Sherri-Ann M.
    Finkelstein, Joel S.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (08): : 2915 - 2921
  • [42] Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis
    Sanad, Z.
    Ellakwa, H.
    Desouky, B.
    CLIMACTERIC, 2011, 14 (03) : 369 - 377
  • [43] BONE MARKERS CTX AND OSTEOCALCIN ASSESSMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS ON ALENDRONATE TREATMENT
    Meceska-Jovcevska, J.
    Subeska-Stratrova, S.
    Janicevik-Ivanovska, D.
    Gruev, T.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S434 - S434
  • [44] ALENDRONATE DISCONTINUATION IN POSTMENOPAUSAL WOMEN TREATED FOR OSTEOPOROSIS
    Powell, Diane
    Than, Soe Soe
    Butler, Robin
    Matthews, Clare
    Garton, Mark
    RHEUMATOLOGY, 2014, 53 : 133 - 134
  • [45] Cyclical alendronate treatment in postmenopausal women with osteoporosis
    Kösüs, A
    Çapar, M
    Kösüs, N
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2005, 91 (02) : 182 - 184
  • [46] Alendronate improves QOL of postmenopausal women with osteoporosis
    Kawate, Hisaya
    Ohnaka, Keizo
    Adachi, Masahiro
    Kono, Suminori
    Ikematsu, Hideyuki
    Matsuo, Hisashi
    Higuchi, Kazumi
    Takayama, Takehiko
    Takayanagi, Ryoichi
    CLINICAL INTERVENTIONS IN AGING, 2010, 5 : 123 - 131
  • [47] Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis
    J. J. Stepan
    D. B. Burr
    J. Li
    Y. L. Ma
    H. Petto
    A. Sipos
    H. Dobnig
    A. Fahrleitner-Pammer
    D. Michalská
    I. Pavo
    Osteoporosis International, 2010, 21 : 2027 - 2036
  • [48] Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment
    Ma, Yanfei L.
    Zeng, Qing Q.
    Chiang, Alan Y.
    Burr, David
    Li, Jiliang
    Dobnig, Harald
    Fahrleitner-Pammer, Astrid
    Michalska, Dana
    Marin, Fernando
    Pavo, Imre
    Stepan, Jan J.
    BONE, 2014, 59 : 139 - 147
  • [49] Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis
    Stepan, J. J.
    Burr, D. B.
    Li, J.
    Ma, Y. L.
    Petto, H.
    Sipos, A.
    Dobnig, H.
    Fahrleitner-Pammer, A.
    Michalska, D.
    Pavo, I.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 (12) : 2027 - 2036
  • [50] Different effects of teriparatide and alendronate on BMD and biomechanical characteristics of the hip in postmenopausal women.
    Bertoldo, F.
    Carbonare, L. Dalle
    Zanatta, M.
    Zenari, S.
    Valenti, M. T.
    Giovanazzi, B.
    Cascio, V. Lo
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S112 - S112
12345